Pharmacotherapy for juvenile spondyloarthritis: an overview of the available therapies

References

• Weiss PF, Colbert RA. Juvenile Spondyloarthritis: A Distinct Form of Juvenile Arthritis. PediatrClin North Am. 2018;65(4):675–690.
   PubMed Web of Science ®Google Scholar
• Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.
   PubMed Web of Science ®Google Scholar
• Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34(10):1218–1227.
   PubMed Web of Science ®Google Scholar
• Prieur AM, Listrat V, Dougados M, et al. Criteria for classification of spondylarthropathies in children. Arch Fr Pediatr. 1993;50:379–385.
   PubMedGoogle Scholar
• Weiß A, Minden K, Listing J, et al. Course of patients with juvenile spondyloarthritis during 4 years of observation, juvenile part of GESPIC. RMD Open. 2017;3(1):e000366.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777–783.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewe R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25–31.
   PubMed Web of Science ®Google Scholar
• Burgos-Vargas R. The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: A critical appraisal for the pediatric rheumatologist. Pediatr Rheumatol Online J. 2012;10(1):14.
   PubMedGoogle Scholar
• Saurenmann RK, Rose JB, Tyrrell P, et al. Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum. 2007;56(6):1974–1984.
   PubMedGoogle Scholar
• Consolaro A, Giancane G, Alongi A, et al. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. Lancet Child Adolesc Health. 2019;3(4):255–263.
   PubMedGoogle Scholar
• Gmuca S, Xiao R, Brandon TG, et al., Multicenter inception cohort of enthesitis-related arthritis: variation in disease characteristics and treatment approaches. Arthritis Res Ther. 2017;19(1):84.
   PubMedGoogle Scholar
• Wang Z, Han Y, Zhang Z, et al. Identification of genes and signaling pathways associated with the pathogenesis of juvenile spondyloarthritis. Mol Med Rep. 2018;18(2):1263–1270.
   PubMed Web of Science ®Google Scholar
• Stoll ML, Weiss PF, Weiss JE, et al. Age and fecal microbial strain-specific differences in patients with spondyloarthritis. Arthritis Res Ther. 2018;20(1):14.
   PubMedGoogle Scholar
• Stoll ML, Kumar R, Morrow CD, et al. Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis. Arthritis Res Ther. 2014;16(6):486.
   PubMed Web of Science ®Google Scholar
• Taxter AJ, Wileyto EP, Behrens EM, et al. Patient-reported outcomes across categories of juvenile idiopathic arthritis. J Rheumatol. 2015;42(10):1914–1921.
   PubMed Web of Science ®Google Scholar
• Weiss PF, Beukelman T, Schanberg LE, et al. CARRA Registry Investigators. Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the childhood arthritis and rheumatology research alliance registry. J Rheumatol. 2012;39(12):2341–2351.
   PubMed Web of Science ®Google Scholar
• Rumsey DG, Guzman J, Rosenberg AM, et al. Children with enthesitis have worse quality of life, function, and pain, irrespective of their juvenile arthritis category. Arthritis Care Res (Hoboken). 2019;10.
   Google Scholar
• Wanders A, Heijde D, Landewé R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756–1765.
   PubMed Web of Science ®Google Scholar
• Shukla A, Rai MK, Prasad N, et al. Short-term non-steroid anti-inflammatory drug use in spondyloarthritis patients induces subclinical acute kidney injury: biomarkers study. Nephron. 2017;135(4):277–286.
   PubMed Web of Science ®Google Scholar
• van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum. 1998;41(5):808–816.
   PubMed Web of Science ®Google Scholar
• Brooks CD. Sulfasalazine for the management of juvenile rheumatoid arthritis. J Rheumatol. 2001;28(4):845–853.
   PubMed Web of Science ®Google Scholar
• Burgos-Vargas R, Vázquez-Mellado J, Pacheco-Tena C, et al. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis. 2002;61(10):941–942.
   PubMed Web of Science ®Google Scholar
• Van Rossum MA, Van Soesbergen RM, Boers M, et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis. 2007;66(11):1518–1524.
   PubMed Web of Science ®Google Scholar
• Cimaz R, Marino A, Martini A. How I treat juvenile idiopathic arthritis: A state of the art review. Autoimmun Rev. 2017;16(10):1008–1015.
   PubMed Web of Science ®Google Scholar
• Haibel H, Brandt HC, Song IH, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis. 2007;66(3):419–421.
   PubMed Web of Science ®Google Scholar
• Horneff G, Foeldvari I, Minden K, et al., Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study. Arthritis Rheumatol. 2015;67(8):2240–2249.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Giannini EH, Huang B, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63:929–936.
   PubMed Web of Science ®Google Scholar
• Horneff G, Burgos-Vargas R, Constantin T, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis. 2014;73:1114–1122.
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Constantin T, Vojinović J, et al. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. Arthritis Res Ther. 2019;21(1):125.
   PubMedGoogle Scholar
• Bugos-Vargas R, Tse SM, Horneff G, et al. A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res (Hoboken). 2015;67:1503–1512.
   PubMed Web of Science ®Google Scholar
• Horneff G, Fitter S, Foeldvari I, et al. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther. 2012;14(5):R230.
   PubMed Web of Science ®Google Scholar
• Papp K, Thaci D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet. 2017;390:40–49.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology. 2012;143:365–374.
   PubMed Web of Science ®Google Scholar
• Faubion WA, Dubinsky M, Ruemmele FM, et al. Long-term efficacy and safety of adalimumab in pediatric patients with Crohn’s disease. Inflamm Bowel Dis. 2017;23:453–460.
   PubMed Web of Science ®Google Scholar
• Burgos-Vargas R, Casasola J. A twelve-week, randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of infliximab in juvenile-onset spondyloarthropathies (JO-SPA). Ann Rheum Dis. 2008;67(SupplII):69.
   Google Scholar
• Burgos-Vargas R, Casasola-Vargas J, Gutierrez-Suarez R. A 3-month, double-blind, placebo-controlled, randomized trial of infliximab in juvenile-onset spondyloarthritis (SpA) and a 52-week open extension. Clin Exp Rheumatol. 2008;26:745.
   Web of Science ®Google Scholar
• Hugle B, Burgos-Vargas R, Inman RD, et al. Long-term outcome of anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis. Clin Exp Rheumatol. 2014;32:424–431.
   PubMed Web of Science ®Google Scholar
• Otten MH, Prince FHM, Twilt M, et al. Tumor necrosis factor–blocking agents for children with enthesitis-related arthritis—data from the Dutch arthritis and biologicals in children register, 1999–2010. J Rheumatol. 2011;38:2258–2263.
   PubMed Web of Science ®Google Scholar
• Weiss PF, Xiao R, Brandon TG, et al., Comparative effectiveness of tumor necrosis factor agents and disease-modifying antirheumatic therapy in children with enthesitis-related arthritis: the first year after diagnosis. J Rheumatol. 2018;45(1):107–114.
   PubMed Web of Science ®Google Scholar
• Otten MH, Prince FH, Ten CR, et al. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective? Ann Rheum Dis. 2011;70(2):337–340.
   PubMed Web of Science ®Google Scholar
• Anink J, Otten MH, Gorter SL, et al. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab? Rheumatology (Oxford). 2013;52(9):1674–1679.
   PubMed Web of Science ®Google Scholar
• Marino A, Giani T, Cimaz R. Risks associated with use of TNF inhibitors in children with rheumatic diseases. Expert Rev Clin Immunol. 2019;15(2):189–198.
   PubMed Web of Science ®Google Scholar
• Marino A, Chiappini E, Cimaz R, et al. Prebiologic Therapy Tuberculosis Screening Experience in a Pediatric Rheumatology Center: TST and IGRA are both necessary. Pediatr Infect Dis J. 2017;36(4):440–441.
   PubMedGoogle Scholar
• Marino A, Real-Fernández F, Rovero P, et al. Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations. Clin Rheumatol. 2018;37(5):1407–1411.
   PubMed Web of Science ®Google Scholar
• Paine A, Ritchlin CT. Targeting the interleukin-23/17 axis in axial spondyloarthritis. Curr Opin Rheumatol. 2016;28:359–367.
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Hermann KG, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of- concept study (TOPAS). Ann Rheum Dis. 2014;73:817–823.
   PubMed Web of Science ®Google Scholar
• Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17 A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705–1713.
   PubMed Web of Science ®Google Scholar
• Mannion ML, McAllister L, Cron RQ, et al. Ustekinumab as a Therapeutic Option for Children With Refractory Enthesitis-Related Arthritis. J Clin Rheumatol. 2016;22(5):282–284.
   PubMed Web of Science ®Google Scholar
• Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum. 2010;62(5):1290–1297.
   PubMed Web of Science ®Google Scholar
• Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis. 2011;70(6):1108–1110.
   PubMed Web of Science ®Google Scholar
• Sieper J, Porter-Brown B, Thompson L, et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo- controlled trials. Ann Rheum Dis. 2014;73(1):95–100.
   PubMed Web of Science ®Google Scholar
• Ringold S, Angeles-Han ST, Beukelman T, et al., 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken). 2019;71(6):717–734.
   PubMed Web of Science ®Google Scholar
• Ward MM, Deodhar A, Gensler LS, et al., 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599–613.
   PubMed Web of Science ®Google Scholar
• Weiss PF, Xiao R, Biko DM, et al. Assessment of sacroiliitis at diagnosis of juvenile spondyloarthritis by radiography, magnetic resonance imaging, and clinical examination. Arthritis Care Res (Hoboken). 2016;68:187–194.
   PubMed Web of Science ®Google Scholar